* PHERECYDES PHARMA *
2006 - IDF
Romainville
(near Paris)
www.pherecydes-pharma.com Discovery, Drugs
Key words: Antibacterials, Phage genes, Emerging problems, Defense, Bio-threat, Libraries of bacteriophages
Mission: to develop, then to introduce new products against multi-resistance bacteria, combining surveillance, detection and therapeutic tools based on phage technology, as a bio-defense and bio-security company
Clients: undisclosed
info@pherecydes-pharma.com
Age: 5 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Gabard (Jérôme) [born 1961, Ph.D., ex-Marketech, DuPont de Nemours]
Sc.Dir.-CSO: Iris (François) [co-founder]
R&D Dir.-CTO: Pouillot (Flavie) [Ph.D. Microbiology, ex-Institut Pasteur]
BusDev:
Financers (Hist.): Biosecurity, Financière de Brienne | Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : 1.15
Focus : Infections
Position : Preclin
Company confirm : 21-Sep-2009 |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .08 | Research : publication in Biosecurity and Bioterrorism on genetically engineered virulent phages to detect and control emergent pathogenic bacteria | R&D | [3 years] |
| 2009 .09 | Nomination : Jérôme Gabard, replacing Thierry Raynaud (since beginning) | ORGN | [2 years] |
| 2009 .08 | Financing (no interest loan) : 0.5 M€, by OSEO, for development and validation of 3 patented technologies, using its predictive integrative biology process (CADI) | DEBT | [2 years] |
| 2009 .08 | 1st round-financing : 1.15 M€, by undisclosed investors | RFINA | [2 years] |
| 2008 .10 | Company move from Paris to Biocitech in Romainville | ORGL | [1 year] |
| 2006 .12 | Company founded by Manuel Géa, as a spin-off from BMSystems | ORGF | [0 year] | Actualisation / Updating: 11-Oct-2010 |
|
